DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $215.10M
• Dividend Yield: N/A
• Average Volume (3M): 97.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: N/A
• EPS Growth: -38.74%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 27,389,774
• 10 Day Avg. Volume: 90,326
• 30 Day Avg. Volume: 97,139
• PEG Ratio: -0.95
• Price to Book (P/B): 63.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.81
• Price Target Upside: 94.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: ―

DBV Technologies SA's stock score is driven by financial instability due to declining revenues and negative returns, which are partially offset by strong recent technical momentum and positive corporate developments. The substantial funding secured for the Viaskin Peanut program is a significant positive, but the stock's valuation remains a concern due to ongoing losses.

Positive Factors

Financial Position

With a solid pro-forma cash position and an additional $180 million in potential warrant proceeds tied to positive VITESSE results, the company enters with enhanced financial flexibility and momentum.

Product Efficacy and Safety

Viaskin Peanut has demonstrated safety and robust efficacy in Phase 3 trials across multiple age groups.

Regulatory Progress

The FDA agreed the safety database from the ongoing Phase 3 VITESSE trial in 4-7 year olds will be sufficient for a BLA submission, allowing DBVT to accelerate its BLA submission.

Negative Factors

Clinical Risks

The VITESSE trial in peanut-allergic children (4–7 years) represents the last major clinical risk for Viaskin, with the Phase 3 trial fully enrolled and using a modified patch informed by previous studies.

Commercialization Risks

Investors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.

Financial Challenges

DBVT ended the year with $33M in cash which management said is sufficient to fund operations into April, so management will need to bring in capital immediately.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

How the Company Makes Money

DBV Technologies makes money by developing and potentially commercializing its pipeline of products based on the Viaskin platform. The company's revenue model is centered around the successful development, approval, and eventual commercialization of its lead product, Viaskin Peanut, as well as other potential products in its pipeline. DBV Technologies may also generate revenue through strategic partnerships, research and development collaborations, and licensing agreements with other pharmaceutical companies. These partnerships could potentially provide upfront payments, milestone payments, and royalties on product sales, contributing to the company's earnings.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA is facing financial instability due to declining revenues and ongoing operational losses. While the balance sheet shows low leverage, cash flow issues and negative returns highlight significant challenges that need to be addressed for improved financial stability.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.16M	2.57M	15.73M	4.80M	5.71M	0.00
	Gross Profit
1.16M	-4.26M	15.73M	-15.50M	-3.57M	-18.82M
	EBIT
-87.28M	-120.74M	-76.43M	-96.63M	-98.61M	-194.80M
	EBITDA
-84.47M	-111.18M	-87.46M	-76.68M	-79.77M	-162.74M
	Net Income Common Stockholders
-113.65M	-113.92M	-72.73M	-96.30M	-97.81M	-195.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.96M	32.46M	141.37M	209.20M	77.30M	240.80M
	Total Assets
50.56M	65.66M	182.99M	246.50M	146.72M	333.87M
	Total Debt
0.00	7.80M	6.55M	10.02M	18.69M	40.63M
	Net Debt
-12.96M	-24.66M	-134.81M	-199.18M	-58.61M	-200.17M
	Total Liabilities
47.69M	38.27M	42.80M	52.00M	47.45M	81.87M
	Stockholders Equity
2.87M	27.39M	140.19M	194.50M	99.27M	252.01M
Cash Flow		Free Cash Flow
-90.46M	-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
	Operating Cash Flow
-89.45M	-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
	Investing Cash Flow
1.00M	-757.00K	-808.00K	-100.00K	-433.00K	―
	Financing Cash Flow
694.00K	587.00K	6.77M	194.10M	274.00K	183.40M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Neutral. The current price of 8.14 is below the 20-day moving average (MA) of 9.60, below the 50-day MA of 8.31, and above the 200-day MA of 5.00, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 40.77 is Neutral, neither overbought nor oversold. The STOCH value of 8.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	57 Neutral	$125.78M	38.10	10.42%	―	0.18%	-55.15%
DBVT	55 Neutral	$215.10M	―	-198.47%	―	―	-38.74%
Sector *	53 Neutral	$5.23B	3.23	-44.27%	2.82%	16.82%	0.11%
CDTX	48 Neutral	$293.96M	―	-299.58%	―	-99.35%	-260.33%
ENGN	42 Neutral	$214.50M	―	-44.21%	―	―	―
CRVS	41 Neutral	$310.77M	―	-100.13%	―	―	-71.53%
CRGX	40 Underperform	$197.37M	―	-65.94%	―	―	―

DBV Technologies SA - American Corporate Events

DBV Technologies Secures $306.9M for Viaskin Peanut Program

On March 27, 2025, DBV Technologies announced a private placement agreement to raise up to $306.9 million (€284.5 million) to advance its Viaskin Peanut program. The financing, led by prominent healthcare investors, will support the company’s efforts to submit a Biologics License Application to the FDA and prepare for a potential U.S. launch. The funding will result in a dilution of existing shareholders but reflects strong investor confidence in the Viaskin Peanut patch’s potential impact on treating pediatric peanut allergies.